Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 7/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618686 | 0.95 | GSK3B (0.37) | GSK3BDYRK1AVCPABL1TRPV1 | |
| SCHEMBL16776286 | 0.95 | GSK3B (0.39) | GSK3BDYRK1AVCPCHRM4ABL1 | |
| SCHEMBL17618594 | 0.91 | FAAH (0.43) | GSK3BDYRK1AVCPCHRM4TRPV1 | |
| SCHEMBL17618624 | 0.91 | GSK3B (0.39) | GSK3BDYRK1AABL1CYP3A4CYP2D6 | |
| SCHEMBL17618539 | 0.90 | CNR2 (0.39) | GSK3BDYRK1AVCPABL1TRPV1 | |
| SCHEMBL17618562 | 0.90 | PRMT5 (0.39) | GSK3BDYRK1ATRPV1FAAHMAP3K5 | |
| SCHEMBL17618388 | 0.90 | VCP (0.43) | VCPCHRM4TRPV1JAK2NTRK1 | |
| SCHEMBL17618566 | 0.90 | TRPV1 (0.40) | DYRK1AABL1TRPV1TNF | |
| SCHEMBL17618604 | 0.89 | FAAH (0.37) | GSK3BDYRK1ATRPV1FAAH | |
| SCHEMBL17618596 | 0.88 | DYRK1A (0.41) | GSK3BDYRK1AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2465/4885DYRK1A 2415/4885VCP 1889/4885 |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 1728/4885DYRK1A 2623/4885VCP 1270/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | GSK3B 1728/4885DYRK1A 2623/4885VCP 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.